VBI Vaccines, Inc. (VBIV) Starts Presentation at LD Micro Conference

VBI Vaccines, Inc., a biopharmaceutical company, is involved in developing novel technologies aimed at expanding vaccine protection in large underserved markets. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. VBI has commenced work for the GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. For more information, visit the company’s website at www.vbivaccines.com.